Used in the treatment of certain B-cell malignancies, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. It targets the CD40 receptor on B cells, blocking the interaction between CD40 and its ligand (CD40L), which plays a key role in B-cell activation, proliferation, and survival. By inhibiting this pathway, the antibody promotes apoptosis of malignant B cells and reduces tumor growth. It has been investigated in clinical trials for its potential to induce tumor regression as a monotherapy or in combination with other agents like rituximab or chemotherapy. Its mechanism also modulates the tumor microenvironment, potentially enhancing immune-mediated antitumor effects.